Company intelligence / Profile preview
Averoa
Grenoble, France
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Averoa has received European marketing authorization for Xoanacyl (ferric citrate coordination complex) for adults with chronic kidney disease to treat iron deficiency and hyperphosphatemia, with additional preclinical and clinical assets targeting renal and metabolic diseases.[3][6]
- Therapeutic areas
- HematologyNephrology
- Modalities
- Small moleculeCompoundDiagnostic test
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Akebia Therapeutics (licensed Xoanacyl/ferric citrate coordination complex from Akebia)
Beyond the preview
Go deeper on Averoa.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Averoa.